SEC Form 4 · accession 0001882764-26-000006

Enliven Therapeutics, Inc. · ELVN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Benjamin Hohl

Officer — CHIEF FINANCIAL OFFICER

Period of report

Jul 17, 2026

Accepted (ET)

Jul 21, 2026 · 5:24 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001672619

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F2	Jul 17, 2026	M	1,072	$2.48	A	52,072	D
Common Stock^F3,F2	Jul 17, 2026	S	324	$49.9715	D	51,748	D
Common Stock^F4,F2	Jul 17, 2026	S	369	$51.4823	D	51,379	D
Common Stock^F5,F2	Jul 17, 2026	S	2,564	$52.318	D	48,815	D
Common Stock^F6,F2	Jul 17, 2026	S	2,638	$53.3825	D	46,177	D
Common Stock^F7,F2	Jul 17, 2026	S	123	$53.8716	D	46,054	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F8	$2.48	Jul 17, 2026	M	1,072	D	—	Aug 2, 2031	Common Stock	1,072	84,966	D

Explanation of responses

F1The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
F2Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3This transaction was executed in multiple trades at prices ranging from $49.72 to $50.3778. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4This transaction was executed in multiple trades at prices ranging from $50.765 to $51.7481. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5This transaction was executed in multiple trades at prices ranging from $51.77 to $52.7695. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6This transaction was executed in multiple trades at prices ranging from $52.77 to $53.7685. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7This transaction was executed in multiple trades at prices ranging from $53.78 to $53.9781. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F8All of the shares subject to this option are fully vested and exercisable as of the date hereof.